Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 1911 Download: 44 Crossref: 1

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 1866 Download: 81 Web of Science: 7 Crossref: 7

Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs

Saori Takamura, Yuichi Teraki, Eri Katayama, Takumi Kawaguchi, Machiko Kawaguchi, Dan Nakano, Tsubasa Tsutsumi, Sumiko Nagoshi, Takekuni Nakama, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):269-272. Published online February 15, 2022

DOI: https://doi.org/10.3350/cmh.2022.0040

View: 5349 Download: 359 Web of Science: 9 Crossref: 9

Review

MAFLD enhances clinical practice for liver disease in the Asia-Pacific region

Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura

Clin Mol Hepatol. 2022;28(2):150-163. Published online November 10, 2021

DOI: https://doi.org/10.3350/cmh.2021.0310

View: 8061 Download: 381 Web of Science: 60 Crossref: 59

1 |

Viewed By 5858	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 5294	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4995	MAFLD: How is it different from NAFLD?
Viewed By 4993	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4615	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 203	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 143	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 119	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 103	MAFLD: How is it different from NAFLD?
Cited By 93	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search